There are 2 clinical trials

Clinical Trials

1 Qatar Prospective RCT Of Therapy Eliminating Covid Transmission

Q-PROTECT is a placebo controlled randomized trial (RCT) to ascertain the efficacy of hydroxychloroquine (HC) alone or, in combination with azithromycin (AZ), in reducing viral load in patients with COVID 19.

NCT04349592 Covid19 Drug: Hydroxychloroquine + Azithromycin Drug: Hydroxychloroquine + Placebo Other: Placebo + Placebo

2 Multicentre, Open Label, Randomised, Adaptative Clinical Trial of Efficacy and Safety of Treatment Regimens in Adult COVID-19 Patients in Senegal

COVID-19 is an emerging pandemic disease affecting most countries including Senegal, caused by the new coronavirus (SARS-CoV-2) which was first detected in the city of Wuhan in China in December 2019. A rapid spread of the disease has occurred at a global scale, associated with a mortality rate of 3.4%. The first case in Africa was declared on February 15, 2020 in Egypt and the first case in Senegal was declared on March 2nd, 2020. In this context, the SEN-CoV-Fadj clinical trial aims to evaluate efficacy and safety, among adults, of different therapeutic regimens considered optimal according to current knowledge, as well as available and adapted to Sub-Saharan Africa. This trial is nested into a cohort of confirmed cases of COVID-19 in Senegal aiming to understand the main clinical, biological, virologic and immunological characteristics of the infection. The protocol of the cohort is based and adapted from the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) / World Health Organization (WHO) Clinical Characterisation Protocol (CCP). Two therapeutic regimens have been eligible in the short term for SEN-CoV-Fadj: Hydroxychloroquine (HCQ) on one hand, and the combination of Hydroxychloroquine and Azithromycin (HCQ + AZM) on the other hand.

NCT04390594 COVID-19 Drug: Hydroxychloroquine Drug: Hydroxychloroquine + Azithromycin

No related HPO nodes (Using clinical trials)